Immix Biopharma: The Hunt for the Medical Bullseye

Immix Biopharma has a highly effective asset with its CAR-T cell therapy NXC-201, which has achieved an astounding response rate of 95% in clinical trials for the rare and life-threatening disease AL amyloidosis. Through a successful capital increase of over $150 million in May 2026, the research-intensive company is financed well into 2027 and can independently take the crucial steps toward market approval. While the stock faces a massive revaluation upon successful approval by the US FDA in 2027, the typical reliance on a clinical phase-3...